CBIO

NASDAQ 已收盘

Crescent Biopharma

12.91 USD
▲+0.51+4.11%
盘后 12.95 +0.31%
2026-11-19
市值
$556.41M
市盈率
—
EPS
-5.56
股息率
—
52 周区间
8.72 – 27.41
成交量
262.06K
Beta
—
目标价
32.33
52W 低 8.7252W 高 27.41
价格走势

公司简介

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head...